Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

Next Previous
Trial Profile

Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orelabrutinib (Primary) ; Rituximab
  • Indications Marginal zone B-cell lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 09 Dec 2024 According to an InnoCare Pharma media release, preliminary results of this study were presented at the ongoing 66th American Society of Hematology (ASH) Annual Meeting.
  • 09 Dec 2024 Results (n=12) presented in the InnoCare Pharma Media Release.
  • 02 Aug 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top